Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.
about
Effect of vaccine administration modality on immunogenicity and efficacy.Anthrax vaccination strategiesMucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbitsA single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challengeEffective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.Advances in device and formulation technologies for pulmonary drug delivery.A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaquesImmunoproteomically identified GBAA_0345, alkyl hydroperoxide reductase subunit C is a potential target for multivalent anthrax vaccine.An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimenKilled but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthraxGeneration and characterization of large-particle aerosols using a center flow tangential aerosol generator with a non-human-primate, head-only aerosol chamberProtective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccineSpray drying and vaccine stabilization.Current progress in pulmonary delivery of measles vaccine.Recent advances in chitosan-based nanoparticulate pulmonary drug delivery.Developments in the formulation and delivery of spray dried vaccines.Intranasal immunization with dry powder vaccines.
P2860
Q27692376-3239A3E8-E662-4EE8-9B75-C0FB60291CBCQ28392248-69A321A5-9B32-49E7-A007-68CA8600B5C5Q28476839-954DEF53-DF48-49FA-94A4-D73F0FED5B10Q33360151-583C5AB5-6F6A-4A89-8E22-BA8D9E709972Q33665793-3A508EAC-7B55-4DB3-A7EC-7C840A1C7FF3Q33962567-FA8048BD-DE15-47A1-9DCE-BA28B0B05661Q34564412-BCA4069A-3AA1-421B-8199-BF9DC47F3766Q34582862-F433B684-58B4-4278-BB8D-B08A8563868AQ35052264-35FA2D97-9772-4A91-AA10-7D57FD0939D7Q36504794-33BC40BB-F3B1-4720-8DCC-CE2051E3348EQ37145046-304CC962-4684-4A83-BDF7-8F4EE5DB940EQ37173907-54A528F9-0D54-4B66-8E83-8EAAFEB9F040Q37190877-F231A266-997B-497E-A4C4-A209C7EDE637Q38062028-74C5A7A7-70DC-48CF-9514-2F95F183097EQ38212517-C8FD9C13-EF90-4A05-BED4-483EBD46E7CEQ38903481-7E7A4FF1-3BF7-4665-9369-953588E51606Q47106090-9DC4F410-8B6B-4B10-AF04-5CEB2628A589Q47584590-12D98766-6074-4E95-8D7F-27649FB85B13
P2860
Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Intranasal administration of d ...... ethal aerosol spore challenge.
@ast
Intranasal administration of d ...... ethal aerosol spore challenge.
@en
Intranasal administration of d ...... ethal aerosol spore challenge.
@nl
type
label
Intranasal administration of d ...... ethal aerosol spore challenge.
@ast
Intranasal administration of d ...... ethal aerosol spore challenge.
@en
Intranasal administration of d ...... ethal aerosol spore challenge.
@nl
prefLabel
Intranasal administration of d ...... ethal aerosol spore challenge.
@ast
Intranasal administration of d ...... ethal aerosol spore challenge.
@en
Intranasal administration of d ...... ethal aerosol spore challenge.
@nl
P2093
P356
P1433
P1476
Intranasal administration of d ...... lethal aerosol spore challenge
@en
P2093
Beverly Dyas
Joanne Huang
John A Mikszta
Matthew S Ferriter
Noel G Harvey
Robert G Ulrich
Vincent J Sullivan
P356
10.4161/HV.3.3.4011
P50
P577
2007-05-13T00:00:00Z